Released on July 01, 2010

Non-clinical studies, focusing on the pharmacodynamics (PD), pharmacokinetics (PK) and safety pharmacology of genetically modified Lactococcus lactis (L. lactis) bacteria, engineered to secrete human Trefoil Factor 1 (hTFF1), were performed to provide proof-of-concept for the treatment of oral...

Released on May 30, 2010

It has been slightly more than a decade since the classic mechanistic paradigm that defined the pathogenesis of mucositis was revised. A five-stage sequence of linked biological events forms the basis for our current understanding of how regimen-related mucosal injury occurs. The first stage is...

Released on May 06, 2010

Objective: To investigate whether cartilage degeneration is prevented or minimized following intraarticular injections of lubricin derived from human synoviocytes in culture, recombinant human PRG4 (rhPRG4), or human synovial fluid (SF) in a rat model of anterior cruciate ligament (ACL)...

Released on January 01, 2010

Background: Mammalian target of rapamycin (mTOR) inhibitors may have efficacy as an intervention for advanced malignancies.  Oral ulceration (OU), reported as mucositis, has been a dose-limiting toxicity for this new class of agents.  An analysis of the appearance, course, and toxicity...

Released on December 01, 2009

The history of mucositis is as old as radiation- and chemotherapy. Despite being regularly reported and documented as one of the worst side effects of cancer therapy, relatively little was appreciated about the complexities of mucositis' pathogenesis until relatively recently. More frustrating...

Released on March 01, 2007

Patients treated with radiotherapy are prone to a constellation of local and systemic toxicities including mucositis, xerostomia, fatigue and anorexia. The biological complexities and similarities underlying the development of toxicities have recently been realized. Mucosal barrier injury is one...